地诺单抗国内价格

Domestic price: Medical Travel found relevant information and learned that denosumab has not yet been launched in China, so we do not know the domestic price of denosumab.

Denosumab (denosumab, also known as AMG-162, trade name Prolia) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B ligand (RANK), inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. On May 28, 2010, the European Commission approved denosumab for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients who are currently ineffective or intolerant to other treatments to reduce the risk of fractures. Denosumab was approved for the first time in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA.

Denosumab is a fully humanized monoclonal antibody (IgG2 monoclonal antibody) that specifically targets receptor activator of nuclear factor-κB ligand (RANKL). It prevents RANKL from binding to its receptor substances, inhibits osteoclast activation and development, reduces bone resorption, and increases bone density. The FDA approved this product for use in postmenopausal women with osteoporosis who are at high risk of fracture. It can help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. This product is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

The specification listed in the United States is 60mg/1ml tube/box, priced at US$1,169.98. The price is relatively high, and most patients cannot afford the high medical expenses. According to Medical Travel, denosumab produced by Amgen of the United States has been launched in Turkey. The specification is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000. It can be said to be high quality and low price. Therefore, more and more patients choose denosumab marketed in Turkey by Amgen of the United States.